How The Rolling Stones “No Filter Tour” Had Zero Visible Technical Components

Legendary rockers The Rolling Stones recently brought their “No Filter Tour” to a close in Paris, where disguise made the show’s sleek visuals possible with four huge, vertical LED walls. One 4x2pro and two 4×4 media servers supported the four monoliths, which kept stage setup streamlined by hiding all electrical components inside the towers. The tour’s vision was to be unique and modern, integrating lighting into the stage structures as much as possible, which culminated in a nearly wireless presentation that wowed audiences around the world.

Creative directors and designers had little lead time after the tour was confirmed, so the priority became bringing elegance and practicality together. That meant that while the band rocked underneath a custom-designed and built roof, lighting and trussing equipment was made a part of the structure itself, keeping the equipment both mobile and striking in appearance. Disguise worked with Solotech video solutions and Neg Earth on meeting lighting demands to execute on a challenging project in minimal time. The results speak for themselves.

On the programming end, limited rehearsal time pushed disguise to bring in Notch’s previsualization solution while also programming as much as possible ahead of time. Even with these preparations, much of the show was operated entirely manually, pushing creative directors to rely on Sock Puppet in addition to Notch, using a grandMA2 full-size console to both program and cue the show start to finish. Once put together, the disguise system was, in the words of Roland Greil who was screens director and disguise programmer, “really reliable as well as easy to work with… [the disguise system] performed flawlessly without any glitches.” All world tours can be counted on to be a massive team effort, but finding a unified vision and the proper tools to execute that vision can’t be counted on so readily. As the Rolling Stones say goodbye to the “No Filter Tour,” they and their team can rest easy knowing they have a proven reliable production team ready.

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More